Ovarian cancer

Acta Oncologica

Volumn 35, Issue SUPPL. 7, 1996, Pages 86-92

  Einhorn, Nina ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; META ANALYSIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; PALLIATIVE THERAPY; PATHOLOGY; RADIOTHERAPY;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; OVARIAN NEOPLASMS; PALLIATIVE CARE; RADIOTHERAPY;

EID: 0008476789     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841869609101668     Document Type: Article

References (74)

1. Einhorn N, Björkholm E. Krebs I. Pettersson F, Tjernberg B. Treatment in early stages of ovarian carcinoma-A randomized study (Abstract). Göteborg: Nordisk Förening för Obstetrik och Gynekologi. 1980. (02/65)
2. Hreshghyshyn MM. Park RC, Blessing JA. et al. The role of adjuvant therapy in stage I ovarian cancer. Am J Obstet Gynecol 1980; 138: 139-145. (C3/86) (Pubitemid 10001207)
3. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage I1 epithelial ovarian cancer. New Engl J of Med 1990; 322: 1021-1027. (Cl/92+ 145)
4. Pecorelli S, Bolis G, Colombo N. et al. Adjuvant therapy in early ovarian cancer: Results of two randomized trials (Abstract). Orlando: SGO. 1994. (02/278)
5. Dembo AJ, Bush RS, Beale FA, Bean HA. Pringle JF. Sturgeon JF. The Princess Margaret Hospital study of ovarian cancer: Stage I. II and asymptomatic I11 presentations. Cancer Treat Rev 1979; 63: 249-254. (C3/54) (Pubitemid 9151510)
6. Smith G. Rutledge FN. Delclos L. Results of chemotherapy as an adjunct to surgery in patients with localized ovarian cancer. Seminars in Oncology 1975: 2 no 3: 277-281. (C2/149)
7. Chiara S, Conte PF. Franzonc P, et al. High-risk early stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. Am J Clin Oncol 1994: 17: 72-76. (C3/70) (Pubitemid 24062739)
8. Kalaassen D. Shelley W, Starreveld A. et al. Early stage ovarian cancer: A randomized clinical trial comparing whole abdominal radiotherapy. Melphalan. and inti-aperitoneal chromic phosphate: A National Cancer Institute of Canada Clinical Trials Group report. J Clin Oncol 1988; 6: 1254-1263. (C1/257)
9. Sell A. Bcrtelsen K. Andersen JE. Stroyer I. Panduros J. Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer. Gynccol Oncol 1990; 37: 367-373. (C2/118) (Pubitemid 20182983)
10. Dembo AJ, Bush RS, Beale FA. et al. Ovarian carcinoma: Improved survival following abdominopelvic irradiation in patients with a completed pelvic operation. Am J Obstet Gynecol 1979; 134: 793 800. (Cl/190)
11. Martinez A. Schray MF. Howes AE. Bagshaw MA. Postoperative radiation therapy for epithelial ovarian cancer: The curative role based on a 24-year experience. J Clin Oncol 1985: 3: 901-911. (R1/152) (Pubitemid 15028559)
12. Goldberg N. Peschel RE. Postoperative abdominopelvic radiation therapy for ovarian cancer. Int J Rad Oncol Bid Phys 1988: 4: 425-429. (R1/74) (Pubitemid 19241695)
13. Fuller DB. Sause WT. Plenk HP, Menlove RL. Analysis of postoperative radiation therapy in stage I through III epithelial ovarian carcinoma. J Clin Oncol 1987: 5: 897-905. (R3/106) (Pubitemid 17119995)
14. Weiser EB. Burke TW, Heller PB. Woodward J, Hoskins WJ, Park RC, Determinants of survival of patients with epithelial ovarian carcinoma following whole abdomen irradiation (WAR). Gynecol Oncol 1988: 30: 201-208. (R1/84)
15. Hart S, Ben-Baruch G, Herczeg E. Hertzberg A. Modan M. Menczer J, Abdominopelvic radiation for stage 1-11 ovarian cancer. Eur J Gyn Oncol 1989: 10: 416-420. (R3/31)
16. Hammond R, Bull C, Houghton CRS, Primary adjunctive whole abdominal radiotherapy in epithelial ovarian cancer: Results of 20-years' experience. Aust NZ J Obstet Gynecol 1992; 32: 267-269. (R3/59)
17. Soper JT. Berchuck A. Clarke-Pearson DL. Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging. Cancer 1991: 68: 725-729. (R3/49)
18. Lanciano R. Randall M. Update on the role of radiotherapy in ovarian cancer. Seminars in Oncology 1991; 18: 233-247. (L1)
19. Dembo Alon J, Radiation therapy in the management of ovarian cancer. Clin Obstet Gynecol 1983; 10: 261-278. (RI/ 147)
20. Denibo Alon J, Abdominopelvie radiotherapy in ovarian cancer. Cancer 1985: 55: 2285-2290. (R1/415)
21. Carey MS, Dembo AJ, Simm JE. Fyles AW, Treger T. Bush RS, Testing the validity of a prognostic classitication in patients with surgically optimal ovarian carcinoma: A 15-year review. Int J Gynecol Cancer 1993; 3: 24-35. (R1/1687) (Pubitemid 23207593)
22. Thomas GM. Dembo AJ, Integrating radiation therapy into the management of ovarian cancer. Cancer 1993: 7: 1710-1718. (L1) (Pubitemid 23056095)
23. Reinfuss M. Kojs Z. Skolyszewski J, External beam radiotherapy in the management of ovarian carcinoma. Radiother Oncol 1993; 26: 26-32. (R 1 /345) (Pubitemid 23063606)
24. Ledermann JA. Dembo AJ, Sturgeon JFG, et al. Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiation. Gynecol Oncol 1991; 41: 30-35. (P2/44)
25. Arian-Schad KS, Kapp DS, Hackl A, et al. Radiation therapy in stage III ovarian cancer following surgery and chemotherapy: Prognostic factors. patterns of relapse. and toxicity: A preliminary report. Gynecol Oncol 1990: 39: 47-55. (R2/20) (Pubitemid 20378258)
26. Potish RA. King LA, Downey GO, Adcock LL. Carson LF. Twiggs LB. The integration of whole abdominal radiotherapy and intraperitoneal cisplatin into the primary management of advanced ovarian carcinoma. Am J Clin Oncol (CCT) 1991: 14: 312-316. (P2/II)
27. Reid GC, Roberts JA. Hopkins MP, et al. Primary treatment of stage Ill ovarian carcinoma with sequential chemotherapy and whole abdominal radiation therapy. Gynecol Oncol 1993: 49: 333-338. (R3/I3) (Pubitemid 23191206)
28. Goldhirsch A. Greiner R, Dreher D. et al. Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy. Cancer 1988; 62: 40-47. (P2/55)
29. Spencer TR. Marks RD. Fenn JO. Jenrette JM, Lutz MH. Intraperitoneal P-32 after negative second-look laparotomy in ovarian carcinoma. Cancer 1989; 63: 2434-2437. (R2/31) (Pubitemid 19152750)
30. Peters WA. Smith MR, Cain JM. Lee RB, Yon JL. Intraperitoncal P-32 is not an effective consolidation therapy after a negative second-look laparotomy for epithelial carcinoma of the ovary. Gyn Oncol 1992: 47: 146-149. (R2/34) (Pubitemid 23001320)
31. Rogers L, Varia M, Halle J, Freddo J, Qaqish 8. O'Keetk T. Fowler W, Phosphorus-32 following negative second-look laparotomy for epithelial ovarian cancer. Gyn Oncol 1993: 50: 144-146. (R1/86)
32. Vergote IB, Winderen M, De Vos LN, Trope CG. Intrapcritoneal radioactive phosphorus therapy in ovarian carcinonia. Cancer 1993; 71: 2250-2260. (C3/50)
33. Bruzzone M, Repetto L, Chiara S, et al. Chemotherapy vcrsus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. Gynecol Oncol 1990; 38: 392-395 (C3/41) (Pubitemid 20362563)
34. Lawton F. Luesley D. Blackledge G. et al. A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. West Midlands Ovarian Cancer Group Trial II. Chi Oncol 1990; 2: 4-9. (C3/108)
35. Lambert HE, Rustin GJS, Gregory WM, Nelstrop AE. A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: A North Thames Ovary Group Study. J Clin Oncol 1993: 11: 440-448. (C2/117) (Pubitemid 23071039)
36. Hacker NF, Berek JS, Burnison CM, Heintz PM. Juillard GJF. Lagasse LD. Whole abdominal radiation as salvage therapy for epithelial ovarian cancer. Obstet Gynecol 1085: 6.5: 60-66. (R3/30)
37. Rosen EM, Goldberg ID, Rose C, et al. Sequential niultiagent chemotherapy and whole abdominal irradiation for stage III ovarian carcinoma. Radiother Oncol 1986: 7. 223-232. (R3/17) (Pubitemid 17225775)
38. Cain JM, Russell AH, Greer BE, Tamimi HK, Figge DC. Whole abdomen radiation for minimal residual epithelial ovarian carcinoma after surgical resection and maxinial lirstline chemotherapy. Gynecol Oncol 1988; 29: 168-175. (R3/10) (Pubitemid 18059537)
39. Solomon HJ, Atkinson KH, Coppleson JVM, et al Ovarian carcinoma: Abdominopelvic irradiation foliowing reexploration. Gynecol Oncol 1988; 31: 396-401. (R3/20)
40. Cheung Alan YC, Salvage radiotherapy for carcinoma of the ovary following chemotherapy. Gynecol Oncol 1988: 70: 15 20. (R3/9)
41. Schray MF. Martinez A. Howes AE, et al. Advanced cpithelial ovarian cancer: Salvage whole abdominal irradiation for patients with recurrent or persistent disease after comhination chemotherapy. J Clin Oncol 1988; 6 (9) SD: 1433 1439. (Rl/53) (Pubitemid 19089032)
42. Morgan L. Chafe W, Mendenhall W, Marcus R. Hyperfractionation of whole-abdomen radiation therapy: Salvage treatment of persistent ovarian carcinoma following chcniotherapy. Gynecol Oncol 1988; 31: 122-134. (R3/15)
43. Reddy SR. Hartsell W, Graham J, et al. Whole-ahdonien radiation therapy in ovarian carcinoma: Its role as a sahage therapeutic modality. Gynecol Oncol 1989; 35: 307-313. (R3/ 30) (Pubitemid 20025892)
44. Stephenson JA. Buchler DA. Abdominopelvic irradiation for persistent advanced ovarian carcinoma. Int J Rad Oncol Biol Phys 1989; 17: 385-388. (R3/15) (Pubitemid 19203088)
45. Kong JS, Peters LJ, Wharton JT, et al. Hyperfractionated split-course whole abdominal radiotherapy for ovarian carcinoma: Tolerance and toxicity. Int J Rad Oncol Biol Phqs 1988; 14: 737-743. (R3/23)
46. Kersh CR. Randall ME. Constable WC, et al. Whole abdominal radiotherapy following cytoreductive surgery and chemotherapy in ovarian carcinoma. Gynecol Oncol 1998. 31 :113-120. (R3/26)
47. Lindner H, Willich H. Atzinger A. Primary adjuvant whole abdominal irradiation in ovarian carcinoma. Int J Rad Oncol Biol Phys 1990; 19: 1203-1206. (R3/84)
48. Eifel PJ, Gershenson DM, Delclos L. Wharton JT. Peters LJ. Twice-daily, split-course abdominopelvic radiation therapy after chemotherapy and positive second-look laparotomy for epithelial ovarian carcinoma. Int J Rad Oncol Biol Phys 1981; 21: 1013-1018. (R3/34)
49. Coltart RS, Nethersell ABW, Brown CH. A pilot study of high dose abdominopelvic radiotherapy following surgery and chemotherapy for stage III epithelial carcinoma of the ovary. Gynecol Oncol 1986: 23: I05 110. (R2/10) (Pubitemid 16133444)
50. Hoskins WJ, Lichter AS, Whittington R. Artman LE. Bihro MC, Park RC, Whole abdominal and pelvic irradiation in patients with minimal disease at cecond-look surgical reassessment for ovarian carcinoma. Gynecol Oncol 1985; 20: 271 280. (R3/8) (Pubitemid 15143753)
51. Fuks Z, Rizel S, Biran S, Chemotherapeutic and surgical induction of pathological complete remission and whole ahdominal irradiation for consolidation does not enhance the cure of stage 111 ovarian carcinoma. J Clin Oncol 1988: 6: 509-516. (P2/29) (Pubitemid 18090700)
52. Haie C, Pejovic-Lenfant MH. Gcorge H, et al. Whole abdominal irradiation following chemotherapy in patients with minimal residual disease after second-look surgery in ovarian carcinoma. Int J Rad Oncol Biol Phys 1989. 17: 15-19. (P2/65) (Pubitemid 19173233)
53. Menczer J, Ben-Baruch G. Modan M. Brenner H. Intrapcritoneal cisplatin chemotherapy vc'rsus abdominopelvic irradiation in ovarian carcinoma patients after second-look laparotomy. Cancer 1989: 63: 1509-1513. (R2/37) (Pubitemid 19093272)
54. Bolis G. Zanaboni F. Vanoli P, et al. Thc impact of whole-abdomen radiotherapy on survival in advanced ovarian cancer patients with minimal residual disease after chemotherapy. Gynecol Oncol 1990: 39: 150 154. (R3/26) (Pubitemid 20372403)
55. Kucera PR. Berman ML, Treadwell P, Sheets EE. Micha JP.Rettenmaier MA. Colman M. DiSaia PJ, Whole-abdominal radiotherapy for patients with minimal residual epithelial ovarian cancer. Gynecol Oncol 1990: 36: 338 341. (R3/l6)
56. Rothenberg ML. Ozols RF. Glatstein E. Stcinherg SM. Rced E. Young RC, Dose-intensibe induction therapy with cyclophosphamide. cisplatin. and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol 1992: 10: 727-734. (P3/9)
57. May LF, Belinson JL. Roland TA. Palliative benefit of radiation therapy in advanced oLarian cmcer. Gynecol Oncol 1990; 37: 408-411. (R2/38) (Pubitemid 20182991)
58. Homesley HD. Scarantino CW, Muss HB. Welander CE. Concurrent chemotherapy and single high-dose plus whole abdominopelvic radiation for persistent ovarian carcinoma. Gynecol Oncol 1989: 34: 170-174. (R3/22) (Pubitemid 19191070)
59. Dembo AJ, Bush RS, Beale FA. A randomized clinical trial of moving strip versus open field uhole abdominal irradiation in patients with invasive epithelial cancer of ovary (Abstract 6571). Proc Am Soc Clin Oncol 1983. (O1)
60. Fyles AW, Dembo AJ, Bush RS, el al. Analysis of complications in patients treated with ahdominopelvic radiation therapy for ovarian carcinoma. Int J Rad Oncol Biol Phys 1992: 22: 847-851. (O1)
61. Einhorn N. von Hamos K. llindmarsh T. Lagergren C. Lundell M, Mellstedt H. Tjernherg B. Radiation in ovarian carcinoma: Evaluation of a us-field technique. Radiother Oncol 1986; 7: 125 131. (O1) (Pubitemid 17180964)
62. Dembo AJ, Epithelial ovarian c'incer: The role of radiotherapy. Int J Rad Oiicol Biol Phys 1991: 21. 835 845. (L1)
63. Calkins A, Lester S, Stehman F, Cline H, Calvo F. Intraoperative radiotherapy in advanced or recurrent gynecologic cancer. Ann Radiol 1989; 32: 502-503. (P3/3) (Pubitemid 20093485)
64. Konski AA, Neisler J, Phibbs G, Bronn DG, Dobelbower RR. A pilot study investigating intraoperative electron beam irradiation in the treatment of ovarian malignancies. Gynecol Oncol 1990; 38: 121-124. (P3/5) (Pubitemid 20206237)
65. Carton GR, Gunderson LL, Webb MJ, et al. Intraoperative radiation therapy in gynecologic cancer: The Mayo Clinic Experience. Gynecol Oncol 1993; 48: 328-332. (P3/1) (Pubitemid 23090800)
66. Paganelli G, Belloni C, Magnani P, et al. Two-step tumour targeting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur J Nucl Med 1992; 19: 322-329. (P1/15)
67. Stewart JSW, Hird V, Sullivan M, Snook D, Epenetos AA. Intraperitoneal radioimmunotherapy for ovarian cancer. Br J Obstet Gynecol 1989; 96: 529-536. (P1/28) (Pubitemid 19146806)
68. Hird V. Stewart JSW, Snook D, et al. Intraperitoneally administered 9OY-labelled monoclonal antibodies as a third line of treatment in ovarian cancer. A phase 1-2 trial: Problems encountered and possible solutions. Br J Cancer 1990; 62 (Suppl X): 48-51. (P1/30) (Pubitemid 20226482)
69. Stewart JSW, Hird V, Snook D, et al. Intraperitoneal Yttrium- 90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol 1990; 8: 1941-1950. (P1/25)
70. Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993; 68: 403-406. (P1/53) (Pubitemid 23229446)
71. Maraveyas A, Snook D, Hird V, et al. Pharmacokinetics and toxicity of an yttrium-90-C1TC-DTPA-HMFGI radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer 1994; 73: 1067-1075. (P1/19) (Pubitemid 24046671)
72. Finkler NJ, Muto MG. Kassis AI, et al. Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer. Gynecol Oncol 1989; 34: 339-344. (P2/20) (Pubitemid 19218574)
73. Muto MG, Finkler NJ, Kassis AI, et al. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. Gynecol Oncol 1992; 45: 265 272. (P1/28)
74. Rubin SC, Kostakoglu L, Divgi C, et al. Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX 35 in patients with epithelial ovarian cancer. Gynecol Oncol 1993: 51: 61-66. (P1/25) (Pubitemid 23339265)